MIRM Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -10.38%, SMA50 0.84%, SMA200 32.39%). The stock’s 14-day RSI is 38.75 (weak momentum), while the ATR of 4.57 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -15.64% below its high and over 149.97% above its low. Average 10-day trading volume of 706.72 thousand shares is below the 3-month average of 1.03 million, indicating normal recent market interest.

Mirum Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.79. This means the shares are trading above this model’s fair value.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) closed at $120.89 USD, gaining $1.85 (1.55%) from the previous close of $119.04. The stock is currently mid-range between its 52-week high and low $50.25 and $130.00. With a market capitalization of about $6.07 billion, Mirum Pharmaceuticals, Inc. is classified as a mid-cap and shows lower-than-market volatility (beta ~0.48). Key stats such as the average daily volume over the past year has been around 1.00 million shares, volume is running light vs its 52-week average. Headquartered in Foster City, CA, Mirum Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Christopher Peetz, the company employs approximately 418 people and listed since July 18, 2019. Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions.

Mirum Pharmaceuticals, Inc. has 50.24 million shares outstanding. The public float is 39.99 million shares, elevated short interest at 13.25% of float. This equals 6.63 million shares. The short ratio is 17.23 days. Institutional investors hold 117.25% of the float. Insiders own 1.4%. BASKETT FOREST holds 4.19 million shares, Walker Paul Edward has 4.19 million shares and Sonsini Peter W. has 4.19 million shares. Over the past six months, insider transactions show net selling. They sold 145.69 thousand shares across 30 transactions.

Mirum Pharmaceuticals, Inc. generated EPS of -$0.86 over the past year. Five-year average earnings growth is 4.14%. The latest quarter delivered EPS of -$13.43. The next quarter is forecast at -$0.21. Next year's EPS is expected at $93.32. Analyst sentiment is bullish. Analyst rating data shows there are 28 Strong Buy ratings, 16 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $175.00 to $77.00. The high target offers 44.76% upside. The low target suggests -36.31% downside. The mean target is $118.41. This offers -2.05% upside. Mirum Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended May 06, 2026, missed forecasts by 3576.73%. The prior quarter beat by -650.0%. Over the last six quarters, Apple has recorded several small beats. These include 81.48% in February 26, 2025.

Mirum Pharmaceuticals, Inc. trades at a P/E ratio of -8.88, slightly below the S&P 500 average, with a price-to-sales ratio of 10.65 and a price-to-book ratio of 29.32 reflecting a rich premium to book value. The P/FCF stands at -35.15, also below market averages. Compared to sector medians, Mirum Pharmaceuticals, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) shares are up 16.33% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Mirum Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -8.88. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $83.96, suggesting -30.55% downside. Our AI forecast model points to short-term strength (12.09% over two weeks), a medium-term rise (32.38% over three months), and a longer-term gain (18.6% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Mirum Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 12.09%, with price expected at $135.50 by July 27, 2026, within a range of $131.46 to $139.39 3-Month Outlook: Projected rise of 32.38%, reaching $160.03 by October 09, 2026, with a range of $158.81 to $161.37. 1-Year Outlook: Projected gain of 18.6%, with price at $143.37 by July 13, 2027, within a range of $139.62 to $148.49.